EBioMedicine

EBioMedicine

EBioMedicineStay current with the latest in all disciplines of life and health sciences with the EBioMedicine app, all with just a tap. Now available for both android smartphones and tablets!• Stay ahead with alerts when new issues are available...

App info


7.2.7
October 11, 2018
200
Android 4.4+

Advertisement

App description


Android App Analysis and Review: EBioMedicine, Developed by Elsevier Inc. Listed in Medical Category. Current Version Is 7.2.7, Updated On 11/10/2018 . According to users reviews on Google Play: EBioMedicine. Achieved Over 200 Installs. EBioMedicine Currently Has 2 Reviews, Average Rating 4.5 Stars

EBioMedicine

Stay current with the latest in all disciplines of life and health sciences with the EBioMedicine app, all with just a tap. Now available for both android smartphones and tablets!
• Stay ahead with alerts when new issues are available and read Articles in Press throughout the month
• Experience innovative digital content with the newly introduced Article enhancements; featuring AudioSlides, Virtual Microscope and the 3D Radiological Viewer
• Get access to the journal content on the app via your institution’s IP
• Enjoy Open Access and Open Archive Content without having to login
• Accessibility support to assist the visually impaired
• Interact with figures, tables, multimedia and supplementary content
• Take notes, highlight articles and share via email and social media
• Personalize your experience with My Reading List and save articles for offline reading

About EBioMedicine

The effective translation of insights gained from biomedical research into improved human health is a global priority. To this end, Elsevier has looked to the leadership of its two leading brands, Cell and The Lancet, to guide the launch of a new comprehensive, online-only open access Elsevier journal, EBioMedicine, focused on forming a community that spans this interface and creates a valuable opportunity for dialogue and collaboration between their respective audiences.

As the communities that border this interface are large and diverse, the scope of EBioMedicine will cover the entire breadth of translational and clinical research within all disciplines of life and health sciences, ranging from basic science to clinical and public/global health science. The journal will also place a high priority on rapid publication. The journal seeks to publish a broad range of research study types, from experimental findings, critical analyses, methodological & technical innovations, and hypotheses to observational epidemiological studies, clinical trials, meta-analyses, and study protocols. In addition, EBioMedicine will publish commentaries, reviews, and viewpoints that enhance the accessibility and applicability of basic research findings for health professionals, and promote a better understanding of clinical challenges for biomedical researchers.

In leveraging the editorial leadership from Cell and The Lancet together with the publishing expertise of Elsevier to create a unique forum for the reputable and speedy publication of research in life and health sciences, we are committed to facilitating and incentivizing a robust and successful pipeline for improved human health globally.


Our privacy policy is here: http://www.elsevier.com/EULA_non-Apple_apps
We are currently offering version 7.2.7. This is our latest, most optimized version. It is suitable for many different devices. Free download directly apk from the Google Play Store or other versions we're hosting. Moreover, you can download without registration and no login required.

We have more than 2000+ available devices for Samsung, Xiaomi, Huawei, Oppo, Vivo, Motorola, LG, Google, OnePlus, Sony, Tablet ... with so many options, it’s easy for you to choose games or software that fit your device.

It can come in handy if there are any country restrictions or any restrictions from the side of your device on the Google App Store.

What's New


•\tBug fixes and performance enhancements

Rate and review on Google Play store


4.5
2 total
5 50.0
4 50.0
3 0
2 0
1 0